IUGN.F Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Imugene Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.05 |
52 Week High | AU$0.10 |
52 Week Low | AU$0.02 |
Beta | 3.21 |
1 Month Change | -28.06% |
3 Month Change | -38.65% |
1 Year Change | -41.52% |
3 Year Change | -68.25% |
5 Year Change | n/a |
Change since IPO | 900.00% |
Recent News & Updates
Recent updates
Shareholder Returns
IUGN.F | US Biotechs | US Market | |
---|---|---|---|
7D | -10.4% | 1.5% | 1.2% |
1Y | -41.5% | 1.1% | 24.7% |
Return vs Industry: IUGN.F underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: IUGN.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
IUGN.F volatility | |
---|---|
IUGN.F Average Weekly Movement | 15.9% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IUGN.F's share price has been volatile over the past 3 months.
Volatility Over Time: IUGN.F's weekly volatility has decreased from 21% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | n/a | Leslie Chong | www.imugene.com |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in phase 2 study for gastric cancer.
Imugene Limited Fundamentals Summary
IUGN.F fundamental statistics | |
---|---|
Market cap | US$403.54m |
Earnings (TTM) | -US$57.88m |
Revenue (TTM) | US$9.75m |
41.4x
P/S Ratio-7.0x
P/E RatioIs IUGN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IUGN.F income statement (TTM) | |
---|---|
Revenue | AU$15.03m |
Cost of Revenue | AU$0 |
Gross Profit | AU$15.03m |
Other Expenses | AU$104.27m |
Earnings | -AU$89.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.012 |
Gross Margin | 100.00% |
Net Profit Margin | -593.63% |
Debt/Equity Ratio | 0% |
How did IUGN.F perform over the long term?
See historical performance and comparison